AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8628597 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 69
Study 1484946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice/slush topical hypothermia (Group I)
Number of subjects: 100
Study 1484946 — intervention group
Group type: COMPARATOR
Intervention: No topical hypothermia (Group II)
Number of subjects: 100
Study 3883733 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of molsidomine three times daily
Number of subjects: 0
Study 3883733 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of molsidomine six times daily
Number of subjects: 0
Study 3883733 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of molsidomine
Number of subjects: 0
Study 3883733 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of sustained-release molsidomine
Number of subjects: 0
Study 3883733 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of molsidomine four times daily
Number of subjects: 0
Study 31696739 — intervention group
Group type: EXPERIMENTAL
Intervention: Levcromakalim
Number of subjects: 0
Study 30048057 — intervention group
Group type: EXPERIMENTAL
Intervention: ERL (Er:YAG laser) with 40 mJ energy, 40 Hz frequency, fluence of 63.66 J/cm2
Number of subjects: 84
Study 30048057 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + PDT (635 nm diode laser, 12 J energy, 30 s irradiation, Toluidine Blue PS application for 60 s)
Number of subjects: 84
Study 30048057 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 84
Study 26888217 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (starting dose 1.5 mg/day; C0 3‐8 ng/mL) with cyclosporine
Number of subjects: 0
Study 26888217 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (starting dose 3 mg/day; C0 3‐8 ng/mL) with tacrolimus
Number of subjects: 0
Study 26888217 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolic acid (1.44 g/day or 2 g/day) with tacrolimus
Number of subjects: 0
Study 26888217 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study 26888217 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory objectives
Number of subjects: 0
Study 25277457 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care C-reactive protein test
Number of subjects: 6500
Study 25277457 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6500
Study 22368149 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 5059
Study 22368149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5059
Study 22368149 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel in Atrial Fibrillation patients
Number of subjects: 5059
Study 21142632 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy (50 IU/kg/week) for 2 weeks
Number of subjects: 0
Study 17705013 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic SPECT performed directly after normal void (Group I)
Number of subjects: 30
Study 17705013 — intervention group
Group type: COMPARATOR
Intervention: Pelvic SPECT preceded by IV injection of 0.5 mg/kg furosemide and IV infusion of 500 cc saline (Group II)
Number of subjects: 30
Study 15728297 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine administered intravenously at the acute phase or orally at the interictal phase
Number of subjects: 0
Study 15728297 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of L-arginine within 30 minutes of a stroke
Number of subjects: 0
Study 11927706 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnitine supplementation (30 mg/kg/d)
Number of subjects: 44
Study 11927706 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TPN without supplemental carnitine)
Number of subjects: 44
Study 11927706 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnitine supplementation
Number of subjects: 44
Study 11927706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9452282 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated mosquito nets and dapsone/pyrimethamine (d/p) prophylaxis
Number of subjects: 1800
Study 9452282 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated mosquito nets
Number of subjects: 1800
Study 9452282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone/pyrimethamine (d/p) prophylaxis
Number of subjects: 1800
Study 9452282 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nets)
Number of subjects: 1800
Study 9452282 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated mosquito nets and d/p prophylaxis (combined)
Number of subjects: 1800
Study 9452282 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated mosquito nets and d/p prophylaxis
Number of subjects: 1800
Study 7610591 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical non-selective and selective beta-adrenoceptor antagonists
Number of subjects: 16
Study 2116265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nutrition (IVN) support
Number of subjects: 12
Study 2116265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intravenous nutrition)
Number of subjects: 12
Study 216027 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg MSH/ACTH4-10
Number of subjects: 36
Study 216027 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg MSH/ACTH4-10
Number of subjects: 36
Study 216027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31059955 — intervention group
Group type: COMPARATOR
Intervention: EBRT alone
Number of subjects: 204
Study 31059955 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT + HDR-BTb
Number of subjects: 204
Study 27893331 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 94
Study 27893331 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 94
Study 27893331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 26624212 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb761
Number of subjects: 2854
Study 26624212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2854
Study 24072634 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone combined with transdermal oestradiol
Number of subjects: 0
Study 24072634 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate combined with transdermal oestradiol
Number of subjects: 0
Study 21802121 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar plasma vaporization of the prostate (BPVP)
Number of subjects: 510
Study 21802121 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection in saline (TURis)
Number of subjects: 510
Study 21802121 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (TURP)
Number of subjects: 510
Study 18931824 — intervention group
Group type: EXPERIMENTAL
Intervention: TG4010 10(8) pfu weekly for 6 weeks, then every 3 weeks
Number of subjects: 40
Study 18931824 — intervention group
Group type: EXPERIMENTAL
Intervention: TG4010 10(8) pfu every 3 weeks
Number of subjects: 40
Study 16393600 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream once daily for 1 month after curettage and electrodesiccation (C&D)
Number of subjects: 20
Study 16393600 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream once daily for 1 month after curettage and electrodesiccation (C&D)
Number of subjects: 20
Study 16393600 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 20
Study 16393600 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 20
Study 12744914 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention
Number of subjects: 120
Study 12744914 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study 11060828 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride
Number of subjects: 1400
Study 11060828 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride with statins (lovastatin, simvastatin, atorvastatin)
Number of subjects: 1400
Study 8828781 — intervention group
Group type: COMPARATOR
Intervention: Injection of rHuEPO into the venous drip chamber using the Fresenius delivery system
Number of subjects: 0
Study 8828781 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of rHuEPO into the venous port
Number of subjects: 0
Study 8828781 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of rHuEPO into the venous drip chamber
Number of subjects: 0
Study 1444083 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical atropine immediately after trabeculectomy
Number of subjects: 38
Study 1444083 — intervention group
Group type: COMPARATOR
Intervention: Topical atropine beginning treatment on the first postoperative day
Number of subjects: 38
Study 3894258 — intervention group
Group type: EXPERIMENTAL
Intervention: tiaprofenic acid (600 mg daily)
Number of subjects: 77
Study 3894258 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen (1.2 g daily)
Number of subjects: 77
Study 31387082 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistance exercise
Number of subjects: 42
Study 31387082 — intervention group
Group type: COMPARATOR
Intervention: High-intensity resistance exercise
Number of subjects: 42
Study 31272982 — intervention group
Group type: EXPERIMENTAL
Intervention: Shield-only protection (shield group)
Number of subjects: 0
Study 31272982 — intervention group
Group type: EXPERIMENTAL
Intervention: Shield and overlapping 0.5 mm Pb panel curtain (curtain group)
Number of subjects: 0
Study 31272982 — intervention group
Group type: EXPERIMENTAL
Intervention: Shield, curtain and additional 75×40 cm, 0.5 mm Pb drape (drape group)
Number of subjects: 0
Study 28650195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based addiction treatment (MBAT)
Number of subjects: 412
Study 28650195 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 412
Study 28650195 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 412
Study 25271396 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW)
Number of subjects: 193
Study 25271396 — intervention group
Group type: COMPARATOR
Intervention: Control Writing (CW)
Number of subjects: 193
Study 23118269 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin
Number of subjects: 82
Study 21607954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir with milk
Number of subjects: 0
Study 21607954 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir with water
Number of subjects: 0
Study 19372711 — intervention group
Group type: EXPERIMENTAL
Intervention: HX575 (recombinant human epoetin alfa)
Number of subjects: 114
Study 19372711 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa (active control)
Number of subjects: 114
Study 16983472 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial graft (Ultrapro)
Number of subjects: 35
Study 16983472 — intervention group
Group type: COMPARATOR
Intervention: Nylon mosquito net
Number of subjects: 35
Study 15284073 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA (3 mg/kg during the initial 5 min and subsequent continuous infusion of 50 mug.kg(‐1).min(‐1) in saline)
Number of subjects: 9
Study 15284073 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (saline)
Number of subjects: 9
Study 11386492 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day)
Number of subjects: 48
Study 11386492 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day)
Number of subjects: 48
Study 11386492 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (400 mg/day)
Number of subjects: 48
Study 11386492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9072590 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 alpha-reductase inhibitor)
Number of subjects: 69
Study 9072590 — intervention group
Group type: COMPARATOR
Intervention: Control group (no family history of BPH)
Number of subjects: 69
Study 9072590 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial BPH
Number of subjects: 69
Study 9072590 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial BPH and sporadic BPH
Number of subjects: 69
Study 7960166 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 ppm F NaF
Number of subjects: 5474
Study 7960166 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 ppm F SMFP
Number of subjects: 5474
Study 2853227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10
Study 2853227 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 10
Study 29446445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 5 µg/kg
Number of subjects: 42
Study 29446445 — intervention group
Group type: COMPARATOR
Intervention: Biosimilar filgrastim 10 µg/kg
Number of subjects: 42
Study 27605969 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise on treadmill and diet
Number of subjects: 80
Study 27605969 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 80
Study 25047675 — intervention group
Group type: EXPERIMENTAL
Intervention: pemetrexed/cisplatin plus CBP501 25mg/m2 IV (Arm A)
Number of subjects: 63
Study 25047675 — intervention group
Group type: COMPARATOR
Intervention: pemetrexed/cisplatin alone (Arm B)
Number of subjects: 63
Study 23738680 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (group A)
Number of subjects: 143
Study 23738680 — intervention group
Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 143
Study 21150554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5-seropositive individuals
Number of subjects: 889
Study 21150554 — intervention group
Group type: COMPARATOR
Intervention: Ad5-seronegative individuals
Number of subjects: 889
Study 18584575 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 42
Study 18584575 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 42
Study 18584575 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone and Acamprosate
Number of subjects: 42
Study 16848265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond with round steel bur
Number of subjects: 0
Study 16848265 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus Total‐Etch with round steel bur
Number of subjects: 0
Study 16848265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond with silicon carbide abrasive paper
Number of subjects: 0
Study 16848265 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus Total‐Etch with silicon carbide abrasive paper
Number of subjects: 0
Study 16848265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond with Er:YAG laser
Number of subjects: 0
Study 16848265 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus Total‐Etch with Er:YAG laser
Number of subjects: 0
Study 14635971 — intervention group
Group type: COMPARATOR
Intervention: Standard asthma care with information on the stepwise treatment approach, a written action plan, and inhaler technique training
Number of subjects: 54
Study 14635971 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional structured allergen evaluation and avoidance advice
Number of subjects: 54
Study 14635971 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional structured allergen evaluation and avoidance advice based on skin prick test results
Number of subjects: 54
Study 10702178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy (LE) formula (419 kJ (100 kcal)*kg(‐)(1)*d(‐)(1))
Number of subjects: 36
Study 10702178 — intervention group
Group type: COMPARATOR
Intervention: Normal-energy (NE) formula (502 kJ (80 kcal)*kg(‐)(1)*d(‐)(1))
Number of subjects: 36
Study 10702178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy (LE) formula
Number of subjects: 36
Study 10702178 — intervention group
Group type: COMPARATOR
Intervention: Normal-energy (NE) formula
Number of subjects: 36
Study 9429041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PCA fentanyl
Number of subjects: 20
Study 9429041 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 20
Study 8397997 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (2.5 mg intravenously)
Number of subjects: 22
Study 8397997 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (control)
Number of subjects: 22
Study 3301709 — intervention group
Group type: EXPERIMENTAL
Intervention: l(‐)ephedrine hydrochloride (50 mg three times a day per os)
Number of subjects: 10
Study 3301709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30071146 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVING ON intervention
Number of subjects: 60
Study 30071146 — intervention group
Group type: COMPARATOR
Intervention: Control booklet
Number of subjects: 60
Study 27289457 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional PENS of dermatome T6 with a 1200 kcal diet (group 1)
Number of subjects: 135
Study 27289457 — intervention group
Group type: EXPERIMENTAL
Intervention: PENS of dermatome T6 with a self-applied patch associated with diet (group 2)
Number of subjects: 135
Study 27289457 — intervention group
Group type: COMPARATOR
Intervention: 1200 kcal diet alone (group 3)
Number of subjects: 135
Study 25071023 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (GLP-1 receptor agonist)
Number of subjects: 48
Study 25071023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 25071023 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin 9-39 (GLP-1 receptor blockade)
Number of subjects: 48
Study 16402745 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative judgment task
Number of subjects: 0
Study 16402745 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential recall or serial position identification task
Number of subjects: 0
Study 16402745 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomous categories on a linear order
Number of subjects: 0
Study 12732401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/daily)
Number of subjects: 80
Study 12732401 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg/daily)
Number of subjects: 80
Study 12732401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate plus Coenzyme Q10 (200+200 mg daily)
Number of subjects: 80
Study 12732401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9798024 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice a day for 14 days)
Number of subjects: 307
Study 9798024 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil (500 mg twice a day for 14 days)
Number of subjects: 307
Study 9798024 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 307
Study 9798024 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil
Number of subjects: 307
Study 8544592 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with epinephrine at varying concentrations (1:400,000, 1:200,000, 1:100,000, 1:50,000)
Number of subjects: 23
Study 8544592 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine
Number of subjects: 23
Study 8544592 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 23
Study 2349932 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (APM) sweetened soda (1150 g per day for 3 weeks)
Number of subjects: 30
Study 2349932 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose corn syrup (HFCS) sweetened soda (1150 g per day for 3 weeks)
Number of subjects: 30
Study 346541 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifyllin
Number of subjects: 172
Study 346541 — intervention group
Group type: EXPERIMENTAL
Intervention: Xantinol‐nicotinate
Number of subjects: 172
Study 346541 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine
Number of subjects: 172
Study 346541 — intervention group
Group type: COMPARATOR
Intervention: Control (no medications)
Number of subjects: 172
Study 30587225 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg doxycycline
Number of subjects: 32
Study 30587225 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg doxycycline
Number of subjects: 32
Study 30587225 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg minocycline
Number of subjects: 32
Study 30587225 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg minocycline
Number of subjects: 32
Study 30587225 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg doxycycline and minocycline
Number of subjects: 32
Study 30587225 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg doxycycline and minocycline
Number of subjects: 32
Study 27525966 — intervention group
Group type: COMPARATOR
Intervention: Vortioxetine (fixed-dose)
Number of subjects: 0
Study 27525966 — intervention group
Group type: COMPARATOR
Intervention: HAM-D6
Number of subjects: 0
Study 27525966 — intervention group
Group type: COMPARATOR
Intervention: HAM-D17, HAM-D21, HAM-D24
Number of subjects: 0
Study 24326004 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine insulin delivery by pen device
Number of subjects: 31
Study 24326004 — intervention group
Group type: COMPARATOR
Intervention: Glargine insulin delivery by vial/syringe
Number of subjects: 31
Study 24326004 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference for insulin delivery method
Number of subjects: 31
Study 22897098 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 140
Study 22897098 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath awareness
Number of subjects: 140
Study 22897098 — intervention group
Group type: COMPARATOR
Intervention: Meditation music (comparison group)
Number of subjects: 140
Study 19890262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (subanesthetic dose)
Number of subjects: 10
Study 19890262 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (placebo)
Number of subjects: 10
Study 18477227 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg/day cyclosporin (CsA) treatment
Number of subjects: 27
Study 18477227 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 27